What TV doesn't, print can't; we deliver.
What TV doesn't, print can't; we deliver.
Highlighting the sector’s potential for growth and self-reliance, Basu emphasized, “We need an ecosystem that nurtures innovation and quality standards in Ayurveda.”
NEW DELHI: In anticipation of the upcoming budget session for 2024, Dr Mandeep Singh Basu, renowned Ayurvedic practitioner and Director of Jagat Pharma and Dr Basu Eye Hospital has articulated key expectations aimed at advancing Ayurveda’s role in modern healthcare.
“With the constant evolution in the modern healthcare sector, the Indian pharmaceutical industry aims to grow not only in its export markets but also to become self-reliant in the long run,” said the Director of Jagat Pharma.
ALSO READ: India, China to drive almost half of global economic growth in 2024
Highlighting the sector’s potential for growth and self-reliance, Basu emphasized, “We need an ecosystem that nurtures innovation and quality standards in Ayurveda.”
Basu stressed the importance of increased investment in research and development, stating, “Enhancing R&D will pave the way for integrating more Ayurvedic practices into mainstream healthcare.” He also called for the establishment of more Ayurvedic colleges across India, akin to the prestigious AIIMS centres, to bolster educational infrastructure.
The integration of artificial intelligence in healthcare was another key point of Basu’s expectations. “An AI-integrated healthcare system will improve diagnostics and patient care,” he noted, underscoring the need for accessibility and affordability in Ayurvedic treatments.
Addressing regional disparities in healthcare access, Basu advocated for expanded medical services in tier-1 and tier-2 cities. “Wider accessibility to quality healthcare is crucial for bridging the urban-rural healthcare divide,” he emphasized.
Basu also urged the government to introduce sustainable tax incentives to support the expansion of the Ayurvedic sector. “These incentives will encourage growth and innovation within the industry,” he asserted.
Looking ahead, Basu outlined the potential benefits of increased funding towards research and development. “Funding R&D will facilitate new clinical trials and developments, enriching Ayurvedic knowledge and advancing scientific practices,” he explained.
Basu described the 2024 budget as an opportunity to create a sustainable ecosystem for Ayurveda. “It’s about promoting individual health and contributing to the nation’s growth while honouring our ancient therapeutic traditions,” he concluded optimistically.
Jagat Pharma, under Dr. Basu’s leadership, stands as a beacon of excellence in Ayurvedic eye care, exemplified by its flagship product, Isotine Eye Drops. Certified by WHO-GMP and recognized for its efficacy in treating various eye ailments, Isotine Eye Drops epitomizes Jagat Pharma’s commitment to blending ancient Ayurvedic principles with contemporary medical advancements.
As the 2024 budget discussions approach, Dr. Mandeep Singh Basu’s advocacy for a progressive healthcare agenda promises to shape policies that not only preserve Ayurvedic heritage but also propel India towards a future where healthcare is inclusive, effective, and grounded in both tradition and innovation. His vision embodies a commitment to holistic healthcare that meets the needs of a diverse and evolving society, ensuring that every individual can access quality medical care that respects and integrates the ancient wisdom of Ayurveda.
